BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.
Oppenheimer 33rd Annual Healthcare Conference:
| Location: | Virtual |
| Format: | Fireside chat and one-on-one meetings |
| Date: | March 13-15, 2023 |
| Fireside chat: | March 13, 10:00am ET |
| Presenter: | Spiro Rombotis |
| Webcast: | Link |
35th Annual Roth Conference:
| Location: | Dana Point, CA |
| Format: | Fireside chat and one-on-one meetings |
| Date: | March 12-14, 2023 |
| Fireside chat: | March 13, 3:00pm PT |
| Presenter: | Paul McBarron |
| Webcast: | Link |
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Contacts
| Company: | Paul McBarron, (908) 517-7330, This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Investor Relations: | Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681, This email address is being protected from spambots. You need JavaScript enabled to view it. |
© Copyright 2023 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
| Last Trade: | US$0.43 |
| Daily Change: | 0.02 4.21 |
| Daily Volume: | 3,093,199 |
| Market Cap: | US$2.690M |
November 14, 2024 November 13, 2024 November 12, 2024 October 23, 2024 October 09, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
